Clinical Trials Logo

Endometrioid Carcinoma clinical trials

View clinical trials related to Endometrioid Carcinoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05080556 Recruiting - Ovarian Cancer Clinical Trials

Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer

ACTOv
Start date: May 24, 2023
Phase: Phase 2
Study type: Interventional

ACTOv will compare standard 3-weekly carboplatin (AUC5), to carboplatin delivered according to an AT regimen. The AT regimen will modify carboplatin dose according to changes in the clinical-standard serum biomarker CA125 as a proxy measure of total tumour burden and an individual patient's response to the most recent chemotherapy treatment. AT could prolong sensitivity to carboplatin and extend tumour control, while simultaneously reducing chemotherapy dose and drug-induced toxicity. Carboplatin is a low cost and low toxicity drug that has an enduring and central role in ovarian cancer treatment.